Xi-Ming Qian, Guo-Qiang Shen, Xiao-Ming Wang
Wuxi No. 9 People's Hospital, Wuxi Municipal Orthopedic Hospital, Jiangsu Province, Wuxi 214000, China.
Zhongguo Xue Xi Chong Bing Fang Zhi Za Zhi. 2019 Feb 19;30(6):682-684. doi: 10.16250/j.32.1374.2019036.
To investigate the seroprevalence of infection in patients with gynecological malignant tumors, so as to provide the evidence for the control of infections in the patients with gynecological malignant tumors.
A total of 327 patients with gynecological malignant tumors were recruited, and 200 women with normal healthy examinations were served as controls. The serum anti- IgG and IgM antibodies were detected by using ELISA, and the seroprevalence was compared between the patients and controls, and among various types of cancers.
The overall seroprevalence of was 26.91% (88/327) in the patients with gynecological malignant tumors, which was significantly higher than that (5.00%) in the healthy volunteers ( = 39.36, <0.01) . The prevalence of anti- IgG antibody in the cancer patients was significantly higher than that in the controls (26.30% vs. 5.00%; = 37.79, <0.01), while the prevalence of anti- IgM antibody in the cancer patients was not significantly different from that in the controls (0.92% . 0; corrected = 0.58, > 0.01) . The positive rates of anti- IgG antibody were 27.68%, 25.47% and 25.69% in ovarian cancer, cervical cancer, and breast cancer patients respectively, which were all significantly higher than those in the controls ( = 32.35, 27.32 and 28.00; all values<0.01); however, there was no significant difference among the various types of cancer patients in the positive rates of anti- IgG antibody ( = 0.17, > 0.05) . In addition, the positive rates of anti- IgM antibody were 1.79%, 0 and 0.92% in ovarian cancer, cervical cancer and breast cancer patients respectively, which was not significantly different from those in the controls (all values > 0.05).
The seroprevalence of infection is high in the patients with gynecological malignant tumors. It is suggested that the prevention and control of infection should be strengthened in these patients.
调查妇科恶性肿瘤患者中[感染名称]的血清流行率，为控制妇科恶性肿瘤患者的[感染名称]感染提供依据。
共纳入327例妇科恶性肿瘤患者，并选取200例健康体检女性作为对照。采用酶联免疫吸附测定法检测血清抗[感染名称]IgG和IgM抗体，比较患者与对照之间以及不同类型癌症患者之间的血清流行率。
妇科恶性肿瘤患者中[感染名称]的总体血清流行率为26.91%（88/327），显著高于健康志愿者中的流行率（5.00%）（χ² = 39.36，P <0.01）。癌症患者中抗[感染名称]IgG抗体的流行率显著高于对照（26.30%对5.00%；χ² = 37.79，P <0.01），而癌症患者中抗[感染名称]IgM抗体的流行率与对照无显著差异（0.92%对0；校正χ² = 0.58，P> 0.01）。卵巢癌、宫颈癌和乳腺癌患者中抗[感染名称]IgG抗体的阳性率分别为27.68%、25.47%和25.69%，均显著高于对照（χ²分别为32.35、27.32和28.00；所有P值<0.01）；然而，不同类型癌症患者之间抗[感染名称]IgG抗体的阳性率无显著差异（χ² = 0.17，P> 0.05）。此外，卵巢癌、宫颈癌和乳腺癌患者中抗[感染名称]IgM抗体的阳性率分别为1.79%、0和0.92%，与对照无显著差异（所有P值> 0.05）。
妇科恶性肿瘤患者中[感染名称]感染的血清流行率较高。建议加强对这些患者[感染名称]感染的预防和控制。
